相关实验视频
Updated: Jul 24, 2026
00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.2K
皮囊性甲状腺癌的表观基因组分析揭示了具有临床影响的不同亚型
Yeongun Lee1, Hyo Jin Park1, Jin Seok Lee2
1Department of Biomedical Sciences, Graduate School of Medical Science, Brain Korea 21 Project, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
NPJ precision oncology
|May 10, 2025
概括
这项研究开发了一种使用细针吸收活检的DNA甲基化方法的微创性测试,以预测乳头甲状腺癌的攻击性. 这种表观遗传生物标记方法有助于外科医生个性化治疗并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子诊断学 分子诊断
背景情况:
- 乳头甲状腺癌 (PTC) 是最常见的甲状腺癌,但预测其攻击性和指导手术决策仍然具有挑战性.
- 目前的诊断方法缺乏最佳手术时间和患者风险分层所需的精度.
- 对于最小侵入性工具来评估瘤行为在手术前是非常必要的.
研究的目的:
- 开发一种基于表观遗传生物标记的系统,用于术前评估乳头甲状腺癌的攻击性.
- 在细针吸收活检 (FNAB) 样本中利用DNA甲基化模式进行风险分层.
- 帮助外科医生做出有关手术规划和个性化治疗策略的明智决策.
主要方法:
- 对甲基组数据的全面分析,以确定甲状腺癌组织中的差异甲基化CpG岛屿.
- 在FNAB样本中开发针对性分析的甲基化特异性原料.
- 55名PTC患者根据已识别的甲基化模式分为预后组的分层.
主要成果:
- 在甲状腺癌中识别了大约7200个CpG岛屿,甲基化发生变化.
- 通过使用甲基化模式,成功地将PTC患者分为两个不同的预后组.
- 证明甲基化特异性原始剂可以准确地分类FNAB样本,与瘤攻击性和生存率相关联.
结论:
- 对PTC的DNA甲基化分析揭示了与瘤攻击性相关的关键表观遗传生物标志物.
- 使用FNAB样本开发的基于甲基化的试验为风险评估提供了一种侵入性最小的手术前工具.
- 这种方法可以帮助外科医生量身定制手术干预措施,并为PTC患者个性化治疗,从而有可能改善结果.
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...